HONG KONG, Sept. 22, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) has announced that the first patient has been dosed in its registrational Phase II study (AK130-202), evaluating AK130, a fully ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback